PRLD
Prelude Therapeutics Inc
3.90$
+1.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | +33.3% | -100.0% | – | – | -13.2% | -18.8% | +24.5% | – | |
| – | – | – | – | – | – | – | – | – | +10.6% | +27.2% | +10.9% | +4.1% | +4.3% | +3.6% | +3.0% | -11.1% | +1.8% | -61.4% | +18.6% | +28.7% | +6.1% | – | – | -11.0% | -0.5% | -1.8% | -1.6% | -6.5% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +33.3% | -110.9% | – | – | -13.2% | -25.7% | +36.2% | – | |
| – | +0.0% | +10.5% | +61.2% | -3.5% | +14.5% | +56.4% | -4.7% | +13.0% | +36.1% | +1.4% | +10.8% | -9.4% | -6.6% | +7.4% | +13.0% | -15.6% | +14.3% | +5.2% | +15.5% | -9.6% | +7.7% | -0.2% | +7.3% | -8.9% | -10.5% | -15.8% | -17.1% | -24.4% | +18.6% | – | |
| – | +0.0% | +134.3% | -10.6% | -3.6% | +38.2% | +71.7% | +71.0% | +12.8% | +0.3% | +47.2% | -3.5% | -4.7% | +9.2% | -7.8% | 0.0% | -3.1% | +2.1% | -4.1% | -1.1% | -1.6% | +10.4% | +3.4% | -21.6% | -6.8% | +10.7% | -18.7% | -4.1% | +3.2% | -2.5% | – | |
| – | +0.0% | +27.5% | +46.6% | -3.5% | +17.4% | +58.7% | +7.2% | +13.0% | +27.1% | +10.4% | +7.1% | -8.2% | -2.7% | +3.2% | +9.8% | -12.8% | +11.3% | +3.0% | +11.0% | -7.3% | +8.2% | +0.6% | +1.2% | -8.5% | -7.0% | -16.4% | -14.6% | -20.1% | +15.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | +389.9% | +153.6% | -78.5% | +549.6% | -52.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -216.5% | – | -125.4% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.